Ayuda
Ir al contenido

Dialnet


Association between ADAM33 S2 and V4 polymorphisms and susceptibility to allergic rhinitis: A meta-analysis

  • Zewen Li [1] ; Fubo Yan [1] ; Zhimin Yang [2] ; Jie Zhou [1] ; Yingchao Chen [1] ; Zhuhua Ding [2]
    1. [1] The Central Hospital of Xiaogan, China
    2. [2] The First People's Hospital of Xiaogan, China
  • Localización: Allergologia et immunopathologia: International journal for clinical and investigate allergology and clinical immunology, ISSN-e 1578-1267, ISSN 0301-0546, Vol. 44, Nº. 2, 2016, págs. 170-176
  • Idioma: inglés
  • Texto completo no disponible (Saber más ...)
  • Resumen
    • Background It has been reported that ADAM33 (a disintegrin and metalloproteinase domain 33) polymorphisms might be associated with susceptibility to allergic rhinitis (AR).

      Objective Owing to mixed and inconclusive results, we conducted a meta-analysis to systematically summarise and clarify the association between ADAM33 S2, V4, T1, T2 and T + 1 polymorphisms and AR risk.

      Methods/results A systematic search of studies on the association of ADAM33 polymorphisms with susceptibility to AR was conducted in Pubmed and Embase. A total of five case–control studies with 1251 patients and 1634 controls were included. Meta-analysis indicated an association between the ADAM33 S2 and AR in allele comparison (G/C:OR = 1.40, 95% CI 1.08–1.82, P = 0.012), heterozygote comparison (CG/CC:OR = 1.24, 95% CI 1.04–1.48, P = 0.015), and dominant comparison (CG+GG/CC:OR = 1.39, 95% CI 1.05–1.85, P = 0.023). The meta-analysis also revealed an association between the ADAM33 V4 and AR in allele comparison (G/C:OR = 1.67, 95% CI 1.01–2.75, P = 0.044). However, no association was found between AR and the ADAM33 T1, T2 and T + 1 polymorphisms in any gene model comparison.

      Conclusions This meta-analysis demonstrates that the ADAM33 S2 and V4 polymorphisms confer susceptibility to AR. However, these results should be interpreted with caution due to limited sample and heterogeneity. Large-scale and well-designed studies are needed to validate our findings.


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus

Opciones de compartir

Opciones de entorno